The first treatment for kids with peanut allergies could be on the market within a year after the results of a late-stage clinical trial were published last week in the New England Journal of Medicine.
The experimental peanut patch, which is being developed by DBV Technologies, is administered through a skin patch that's worn for 22 hours a day for a year.
It delivers a tiny dose of peanut protein equivalent to about a thousandth of a peanut.
After a year, 67% of kids who wore the patch were able to tolerate a higher dose of peanuts, compared to 33.5% of kids who received a placebo, NBC News reports.
"This is very good news for toddlers and their families as the next step toward a future with more treatments for food allergies," an allergist not involved with the study writes in an editorial accompanying the paper.
The study included 362 toddlers between one and three years old with peanut allergies.
The patch is still only experimental, and it's not clear when it will be available for consumers.
A customized collection of grant news from foundations and the federal government from around the Web.
In the world of social enterprises, failure is a cringe-worthy moment nobody wants to talk about. But, social entrepreneurs can benefit from their failures.